Vorinostat

Phase 1Completed

0 watching 0 views this week💤 Quiet

Hype Score

Development Stage

✓

Pre-clinical

Phase 1

Phase 2

Phase 3

Approved

Indication / Disease

Brain Metastases

Conditions

Brain Metastases

Trial Timeline

Mar 1, 2009 → Mar 1, 2015

NCT ID

NCT00838929

About Vorinostat

Vorinostat is a phase 1 stage product being developed by Merck for Brain Metastases. The current trial status is completed. This product is registered under clinical trial identifier NCT00838929. Target conditions include Brain Metastases.

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (17)

NCT ID	Phase	Status	Start	Completion	Indication
NCT01365065	Phase 2	UNKNOWN	May 1, 2011	Jan 1, 2018	HIV Positive
NCT01319383	Phase 1/2	Completed	Feb 1, 2011	Mar 31, 2016	HIV-1 Infection
NCT00918489	Phase 2	Completed	May 1, 2010	Sep 1, 2013	Soft Tissue Sarcoma
NCT01000155	Phase 2	Terminated	Oct 1, 2009	Oct 1, 2014	Sickle Cell Disease
NCT00821951	Phase 1	Completed	May 1, 2009	Jul 1, 2012	Non-Small Cell Lung Cancer (NSCLC)
NCT00831493	Phase 1/2	Terminated	May 1, 2009	Oct 1, 2010	Pancreatic Cancer
NCT00875056	Phase 2	Completed	Apr 15, 2009	Feb 8, 2019	Lymphoma
NCT00735826	Pre-clinical	Completed	Mar 1, 2009	Jul 1, 2012	Aerodigestive Tract Cancer
NCT00838929	Phase 1	Completed	Mar 1, 2009	Mar 1, 2015	Brain Metastases
NCT00719875	Phase 1	Completed	Dec 1, 2008	Jun 1, 2013	Advanced Breast Cancer
NCT00771472	Phase 1	Completed	Aug 1, 2008	Jul 1, 2011	Lymphoma
NCT00776503	Phase 1/2	Completed	May 1, 2008	Nov 1, 2011	Myelodysplastic Syndromes
NCT00561418	Phase 1	Completed	Nov 1, 2007	May 1, 2013	Lymphoma
NCT00416130	Phase 1/2	UNKNOWN	Jan 1, 2007	Jan 1, 2015	Breast Cancer
NCT00907738	Phase 2	Completed	Aug 1, 2005	Jun 1, 2010	Advanced Cancer
NCT00127127	Phase 1	Completed	Jun 10, 2005	Aug 21, 2009	Tumors
NCT00127140	Phase 1	Completed	Jun 1, 2005	Apr 1, 2012	Lymphoma

Competing Products

20 competing products in Brain Metastases

See all competitors

Product	Company	Stage	Hype Score
Abemaciclib + Endocrine therapy	Eli Lilly	Phase 1/2	41
Duloxetine + Sugar pill	Eli Lilly	Phase 2	52
Neurosteroid enantiomer	Oragenics	Phase 2	44
Patritumab deruxtecan	Daiichi Sankyo	Phase 2	52
filgrastim + exatecan mesylate	Daiichi Sankyo	Phase 1	33
Eribulin Mesylate	Eisai	Phase 1	33
Pembrolizumab + Lenvatinib	Eisai	Phase 2	52
Palonosetron (Aloxi) and Dexamethasone	Eisai	Phase 2	52
GLIADEL	Eisai	Phase 2	52
Nivolumab + Temozolomide	Ono Pharmaceutical	Phase 3	77
Nivolumab + Temozolomide	Ono Pharmaceutical	Phase 3	77
Prexasertib + Cyclophosphamide + Gemcitabine + filgrastim + peg-filgrastim	Eli Lilly	Phase 1	33
abemaciclib + abemaciclib	Eli Lilly	Phase 2	52
JNJ-17299425	Johnson & Johnson	Phase 2	52
ABT-888	AbbVie	Phase 1	33
Veliparib + Placebo	AbbVie	Phase 2	52
Iressa (Gefitinib)	AstraZeneca	Phase 2	52
Trastuzumab deruxtecan	AstraZeneca	Phase 2	52
Exenatide	AstraZeneca	Approved	85
AZD5213	AstraZeneca	Phase 1	33

Other Products from Merck

DuleraApproved

ImipenemApproved

Mavenclad®Approved

raltegravir + PlaceboApproved

alendronate sodiumApproved